No Data
H.C. Wainwright Maintains Instil Bio(TIL.US) With Buy Rating, Maintains Target Price $110
Strategic Acquisitions and Market Potential Position Instil Bio's SYN-2510 as a Buy With High Growth Prospects
BNTX to Boost Oncology Pipeline With Biotheus Acquisition, Stock Up
Merck to Buy Rights to Chinese Cancer Drug for up to $3.3B
H.C. Wainwright Maintains Instil Bio(TIL.US) With Buy Rating, Cuts Target Price to $110
HC Wainwright & Co. Maintains Buy on Instil Bio, Lowers Price Target to $110
No Data
No Data